No longer just a catch phrase, digital transformation in pharma manufacturing is more critical today than ever before and the industry is getting on board.
Watch Now
pharmaintelligence
Patient Support Programs (PSPs) have changed dramatically over the past decade; they have become global activities, and grown significantly in scale and complexity. While PSPs are also an increasingly valuable resource for pharmacovigilance due to the extensive patient safety data they generate, they have suffered from the traditional lack of standardized mechanisms for recording, reconciling and managing this data, resulting in resource heavy processes, and a lost opportunity for deeper product understanding for Pharma. Fortunately, new technologies are helping to tackle this challenge.
Watch Now
N-Nitrosamine impurity findings in marketed formulations of rifampin have disrupted drug development. As a strong cytochrome P450 3A4 (CYP3A4) inducer, rifampin was regularly co-administered with investigational products
Watch Now
questexweb
It was reported that over 79,000 people died of flu in the U.S. in the winter of 2017-2018, which was the highest death toll in four decades.1 It seems like the 2018-2019 flu season isn’t so bad. How are sales of OTC drugs impacted by the severity of flu seasons? Are there any opportunities for new products to capture market share? How can companies ensure reliable supply of OTC medications based upon expected spikes in demand?
Watch Now